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Summary 
Crosslinking of CD2 antigen on T  lymphocytes and natural killer (NK) cells leads to a rise 
in cytoplasmic-free Ca  2+  concentration ([Ca2+]i).  However, CD2  seems unlikely to interact 
directly with the second messenger pathways since signaling via CD2 is poor in T  cells that 
lack the T cell receptor (TCR) and is absent in L cells or insect cells that express CD2. In contrast, 
NK cells that are also TCR-  can be triggered via CD2,  but it is unclear as to whether the 
CD16 Fc receptor (FcR) may facilitate this effect. The CD16 transmembrane molecule is expressed 
in a complex with the zeta homodimer or the ~'/'y heterodimer and these dimers are also associated 
with the TCR complex. Thus, it seemed that ~" chains may provide the link between signaling 
on NK cells and T  cells. This could be tested on TCK-  cells since when CD16 is transfected 
into T  cells it is expressed in a complex with TCK ~" homodimer or the ~'/'g heterodimer. At 
first, potentiation of CD2 signaling was seen on TCP,- Jurkat cells expressing CD16, but this 
was found to be dependent on trace levels (1%) of IgG in F(ab')2 antibody preparations. With 
pure F(ab')2, the effect was lost. Signaling on a rat NK cell line was also re-examined with F(ab')2 
antibodies that had no IgG contamination, and again no signal transduction via CD2 was seen. 
We thus conclude that there is no clear evidence for potent signaling via CD2 on cells that lack 
a TCP, complex and that TCR ~" chain expressed at the cell surface is not sufficient to potentiate 
signaling via CD2 as measured by an increase in  [Ca2+]i. 
C 
D2 is a glycoprotein of 50 kD that is expressed on thymo- 
cytes, T lymphocytes, and NK cells (1). The molecule 
consists of two Ig-like domains followed by a single trans- 
membrane sequence and a COOH-terminal cytoplasmic re- 
gion of 116-117 residues (2).  CD2 can mediate adhesion of 
T cells to other cells by binding to its ligand LFA-3, which 
has  a similar structure to CD2  (2a). 
T  lymphocytes can be activated in an antigen-dependent 
manner through the TCR/CD3  complex or in vitro in an 
antigen-independent manner through one of several surface 
molecules including CD2. Stimulation through CD2 has been 
referred to as the alternative activation pathway (3) and, as 
in the case of activation through the TCR/CD3  complex, 
leads to inositol phosphate and diacylglycerol mobilization, 
a rise in cytoplasmic-free Ca  2+ concentration ([Ca2+]i) 1 (1, 
1Abbreviations used  in  this paper: [Ca2+]i,  cytoplasmic-free  Ca  2+ 
concentration;  DAB,  Dulbecco's A  +  B  PBS solution;  GPI,  glycosyl 
phosphatidylinositol;  PI-PLC,  glycosyl-phosphatidyl  inositol-specific 
phospholipase C; RAM,  rabbit anti-mouse IgG. 
2), phosphorylation of the ~" chain of the TCR/CD3 com- 
plex on tyrosine residues (4), expression of the IL-2R, IL-2 
secretion, and mitogenesis (1, 2). For human and rat CD2, 
the cytoplasmic domain is required for signal transduction 
as measured by increases in [Ca2+]i  or IL-2 secretion (1, 2). 
A number of studies have indicated a functional interrela- 
tionship between CD2 and the TCR/CD3 complex (1, 2). 
CD2 can synergize with the TCP, by enhancing antigen- 
mediated  IL-2 secretion  in  T  cell  hybridomas  (5).  In 
TCR/CD3-  T  cell lines,  crosslinking  of CD2  functions 
poorly in inducing elevations in [Ca2+]i  (1, 2) or Ib2 secre- 
tion (1). CD2 is dependent on the presence of CD3 for the 
induction of MAP-2 kinase activity (6). CD2 does not trans- 
duce activation signals if expressed on an insect gut epithelial 
cell line by using the Baculovirus system (7) or on a murine 
L fibroblast line (8). Downmodulation of the TCR/CD3 com- 
plex by means of mAbs prevents subsequent stimulation via 
CD2  (9). 
TCK-independent signaling via CD2 has been reported 
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Volume 174  December 1991  1407-1415 to occur in NK cells. NK cells are TCR/CD3-,  but they 
express  the transmembrane form of the Fc receptor CD16 
or Fcq'RIIIA, henceforth called CD16 (T/M), in a complex 
with ~" chain homodimers or ~'/3/heterodimers, as found in 
the TCR/CD3 complex (10). CD16 (T/M) mediates signal 
transduction on NK ceils since its interaction with immune 
complexes  or mAbs induces increases in [Ca2+]i, mobiliza- 
tion of inositol phosphates (11), and tyrosine phosphoryla- 
tion of the ~" chain (12). CD16 can also be expressed  in a 
form anchored by a glycosyl-phosphatidyl inositol anchor, 
CD16 (GPI), and this form does not mediate signal trans- 
duction (13). 
There have been conflicting reports about the signal trans- 
duction ability of CD2 on CD3-/CD16 + NK cells. Cross- 
/inking of CD2 on the surface of a rat NK-like cell line leads 
to the generation of inositol phosphate (14). Anti-CD2 mAb 
use in the form of ascites caused NK ceils to lyse Fctk-expressing 
NK cell-resistant targets (15). In NK cells stimulated with 
an (anti-CD2  x  anti-DNP) conjugate, induction of cyto- 
toxicity via CD2 was shown to be dependent on interplay 
with CD16 (16). Anti-CD2 IgG of the IgG3 isotype caused 
a rise in [Ca  2+ ]i and an increase in cytolytic activity in cul- 
tured NK cells. These effects were not seen when the anti- 
CD2  mAb  was  used  in  the  form  of F(ab')2 fragments, 
demonstrating that activation of the lytic response  in NK 
ceils requires  cocrosslinking of CD2 and CD16 (T/M) (17). 
The common element found in the TCK and CD16 (T/M) 
signal transduction complexes  of T  cells and NK cells are 
the disulphide-linked dimers ~'/~, g/y, and 3'/3'.  This sug- 
gested that these dimers are crucial for signaling via the TCR 
and CD16 (T/M). We hypothesized that expression of CD16 
(T/M) with its associated dimers might restore signaling via 
CD2 in TCR/CD3- Jurkat cells and tested this hypothesis 
by transfection of CD16  (T/M) cDNA into such cells. 
Materials  and Methods 
Cell Lines.  The TCR- Jurkat cell lineJ.RT3-T3.5 (18) and the 
TCR § Jurkat cell line E6-1 (19) were both obtained from Arthur 
Weiss (UCSF, CA). The E6-1 Jurkat cells were subcloned and a 
clone designated J5 was selected for further use. 
The rat NK cell line RNK-16 was obtained from John Imboden 
(UCSF, CA) (14). This ceLl  line was contaminated  with mycoplasma 
and was treated  with 40 #g/10 ml BM-CYCLIN  (Boehringer  Mann- 
helm, Sussex, UK). The rat cell line A181 was obtained from Leon 
Cobb (MRC Radiobiology Unit, Oxon) (L.L. Spruyt and M.J. 
Glennie, unpublished results). This line recently arose in a Fisher 
rat and was grown by passage through Fisher rats. It was used after 
the third passage and resembled the line RNK-16 in that it was 
CD2 +,  CD3-,  and  NKR-Pl+.  All cell lines were grown in 
medium containing RPMI 1640 supplemented with 10%  heat- 
inactivated FCS, 50/~M 2-ME, and antibiotics. 
MonoclonalAntibodies.  The following mAbs were used: mouse 
anti-human CD3, OKT3 (IgG2a) (20); mouse anti-human CD2, 
OKTll (IgG1) (21); GT2 (IgG1), which was kindly donated by 
Doreen Cantrell (ICRF, London) (22); mouse anti-human CD16, 
3G8 (IgG1), which was kindly donated by David Segal (NIH, 
Bethesda, MD) (23); mouse anti-rat CD2;  OX-34 (IgG2a) (2); 
mouse anti-mouse TCK-B, F23.1 (IgG2a) (24); mouse anti-rat 
CD3, 1F4 (IgM), which was kindly donated by Tosiyuki Tanaka 
(Tohoku University, Japan) (25); mouse anti-human 'A' erythro- 
cytes, W6/1 (IgM) (not published); mouse anti-human C3b inac- 
tivator, OX-21 (IgG1). The mouse anti-rat mAb 3.2.3 (IgG1), which 
was obtained from Serotec (Kidlington UK), recognizes  an antigen, 
NKR-PI, on the surface of rat NK cells (26). Bispecific mouse 
anti-human  CD2  (GT2  x  OKTll)  F(ab'3,)2 comprising one 
OKTll Fab'q, arm and one GT2 Fab"r arm was prepared by  joining 
the individual  antibody Fab'~,  fragments  via a stable thioether linkage 
as previously described (27). These F(ab')2 fragments were then 
purified over a highly specific sheep anti-mouse Fc immunosor- 
bent column. 
Expression Vectors  for CD16 T/M and CD16 GPI.  cDNA clones 
Fc'yRIII-1 (CD16 GPI) and Fe3,RIII-2 (CD16 T/M) were obtained 
from Jeffrey Ravetch (Memorial Sloan-Kettering Cancer Center, 
New York) (28) and were blunt-cloned into the BamHI site of the 
expression vector pKG5 (2). 
Transfection by Electro, ration.  Cells  were transfected  by electropo- 
ration as described previously (2). Cells containing the neo gene 
were selected with G418 at a concentration of I mg/ml. Subse- 
quently, cells expressing  high levels of CD16 were selected  by FACS 
(Becton Dickinson & Co., Mountain View, CA). 
Flow Cytometric Analysis.  Cells, 3  x  106 per sample, were in- 
cubated with 50 #1 of  antibody (tissue culture supematant) for 1 h 
on ice. CeLls  were washed twice at 4~  in I ml of PBS containing 
0.25% BSA (PBS/BSA) and 10 ram NaNs, and were subsequently 
incubated in 50 #l of FITC-conjugated rabbit anti-mouse  IgG 
(RAM) (15 #g/ml) (29). Cells were resuspended in 0.4 ml PBS/ 
BSA and analyzed on a FACScan  |  (Becton Dickinson & Co.). 
Saturation Binding Assay.  Cells  were incubated with saturating 
amounts of mAbs as for flow cytometric analysis. For CD2, the 
primary mAb used was OKTll (IgG1) while the mAb 3G8 (IgG1) 
was used for CD16. After three washes in 1 ml of PBS/BSA at 
4~  cells were incubated with 25 #1 of lzsI-RAM IgG F(ab')2 at 
30 #g/ml (500,000 cpm). After I h on ice, cells were washed three 
times as above and bound radioactivity was counted. Site numbers 
were determined by comparison of radioactivity bound by the 
W3/25 mAb to rat thymocytes (15,000 sites per cell) (30). 
Glycosyl-Phosphatidfl Ionositol-specific Phospholipase C  (PI-PLC) 
7~eatment of  Jurkat Cells.  CD16  (GPI)  + and CD16 (T/M) + Jurkat 
cells (107 each) were incubated with 1.8  x  10 -3 U  of BaciUus 
thuringiensis PI-PLC (Peninsula  Laboratories, Merseyside, UK) in 
200 #i of PBS/BSA 0.5% at 37~  for 1 h. The cells were washed 
twice with PBS/BSA 0.5%, split into three aliquots of 3.3  x  106 
cells, and labeled for flow cytometric analysis as described above. 
Measurement of[Ca2+],  ￿9  [Ca2§  was determined as described 
previously (31). 
Preparation of F(aP)2 Fragments.  OX-34  F(ab')2 was prepared by 
pepsin digestion of IgG in Na acetate buffer (pH 4.0) for 10 h at 
37~  (32). After dialysis in  a Tris saline buffer (pH  7.6), the 
F(ab')2 and Fab fragments were separated by gel filtration on a 
Sephadex G-200 column (Pharmacia Ltd., Bucks, UK). The frac- 
tions containing the F(ab')z were pooled and passed over a pro- 
tein A (Pharmacia  Ltd.) column three times. This reduced the con- 
tamination of IgG to <0.001% (data not shown). 
F(ab')z RAM was first prepared by pepsin digestion and gel 
filtration, and samples  judged to be free of  IgG as assessed  by SDS- 
PAGE were pooled (29). Analysis  by inhibition of  protein A binding 
showed the presence of 1% IgG (Fig. 1). The F(ab')2 RAM was 
then fitrther purified  by passage over a protein A column three times. 
This reduced the contamination to <0.0001% (Fig. 1). 
Inhi~tion Binding Assay.  F(ab')z  RAM was assayed  for the pres- 
ence of IgG by inhibition of an indirect radioactive binding assay 
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Figure 1.  Inhibition  binding assay to quantitate the 
amount of IgG in the preparations of F(ab')2 RAM be- 
fore and after passage over a protein A column. Ex- 
perimental details are given in Materials and Methods. 
using [t~I]protein A (Amersham International, Amersham, UK). 
For targets in the assay, rabbit IgG (RAM) was coated onto wells 
of a flexible assay plate (3911; Falcon Labware, Oxnard, CA) by 
incubation of 50/~1 at 50/zg/ml for 30 min at 20~  The unbound 
RAM was then removed  by washing with Dulbecco's  A + B PBS 
solution (DAB) (Oxoid Ltd., Basingstoke, UK). The plate was 
blocked  with DAB/BSA  0.5% and then washed  again using DAB. 
A range of serial dilutions were made of RAM and F(ab')2 RAM 
and 50 td aliquots were added to 120,000 cpm of mI-protein A 
in 25/A and incubated at 4~  for 1 h. 50/xl aliquots were then 
transferred to the plate coated with RAM and incubated at 4~ 
for 1 h, washed, and dried at 37~  The bound radioactivity  was 
counted on a gamma counter. 
Results 
Expression of Two Molecular Forms of CD16  on  TCR- 
Jurkat Cells.  cDNA encoding the glycosyl phosphatidylino- 
sitol (GPI)-linked and T/M forms of CD16 were cloned into 
the expression vector pKG5 and transfected into the TCR- 
Jurkat cell lineJ.RT3-T3.5. Flow cytometry showed that the 
two molecular forms of CD16 were similarly expressed on 
the transfected Jurkat cells. Control and transfected cells were 
homogeneously positive for CD2, whereas CD3 was not de- 
tectable (Fig. 2). The expression of the two forms of CD16 
and of CD2 was quantitated by a saturation  binding assay. 
CD16 (T/M) and CD16 (GPI) were expressed at 2.4  x  10  + 
o~ 
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Figure 2.  Flow  cytometric  analysis 
of TCR- Jurkat cells expressing the 
(T/M) or GPI-linked  form of CD16. 
Untransfected  TCR- Jurkat cells  were 
used as controls.  The dotted  lines  show 
labeling  with an isotylx--matched  nega- 
tive  control  mAb F23.1  which  was used 
in the case  of OKT3, and OX-21 in the 
case of OKTll and 3G8. 
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Figure 3.  PI-PLC treatment ofTCR- Jurkat cells expressing the (T/M) 
or GPI-linked  form of CD16.  Cells were incubated  in PBS/BSA 0.5% 
with or without PI-PLC. The dotted lines show labeling with an isotype 
matched negative control mAb, OX-21.  The CD16 antigen was labeled 
with the mAb 3G8. 
molecules per cell and 3.4  ￿  104 molecules per cell, respec- 
tively, while CD2 was expressed at 4  x  104 molecules per 
cell in all three lines. CD16 was cleaved from the surface of 
the CD16 (GPI) line by PI-PLC treatment. This enzyme did 
not  cleave  CD16  from  the  surface of the  CD16  (T/M) + 
Jurkat cell line (Fig.  3). 
Ca 2§  Signals  Triggered via  CD2 and CD16 in  Transfected 
Jurkat Cell Lines.  Increases  in [Ca2+]i were determined in 
Jurkat cells,  untransfected or expressing the two forms of 
CD16, after stimulation with antibodies directed against CD3, 
CD2,  and CD16.  The primary antibodies were crosslinked 
by F(ab')2 fragments of RAM containing either 1% IgG or 
<0.0001%  IgG. Representative profiles of Ca  2+  signals are 
shown in Fig.  4,  and quantitative data are shown in Table 
1. As could be expected from the inability to detect surface 
expression of CD3 as measured by flow cytometry, only small 
increases  in [Ca2+]i were seen when CD3 was crosslinked 
using F(ab')2 fragments of anti-CD3  mAbs. 
Signaling via CD16 required the addition of a crosslinker 
and was only seen in the cells expressing CD16 (T/M), not 
in the cells expressing CD16 (GPI).  The signal transduced 
via CD16 in the CD16 (T/M) population was of the same 
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Figure 4.  [Ca2+]i  responses of TCR- Jurkat cells expressing the T/M form of CD16 using as crosslinker F(ab')2 RAM with 1%  IgG and F(ab')2 
RAM with <0.0001%  IgG. Untransfected  Jurkat cells or TCR- Jurkat cells expressing the GPI-linked form of CD16 were used as controls and were 
crosslinked with F(ab')2 RAM containing 1% IgG. The cells were loaded with fura-2 AM, and at the time of points indicated (~), anti-human CD2 
mAb (bispecific [GT2  x  OKTll] F[ab'3']2) (2.5 #g/ml final concentration)  or anti-human CD3 mAb (OKT3 F[ab']2) (0.5/~g/ml final concentration) 
were added. In addition  cells were pre-incubated  for 1 h on ice in 50 #1 of 50/~g/ml anti-human CD16 mAb (3G8) and then diluted  to 2 ml before 
addition  of the crosslinking  mAb. The addition  of the crosslinking  mAb (20/~g/ml final concentration)  is indicated  ( 1~ ). Values following the A 
indicate increases in [Ca2+]i in nanomolar  above the base lines and the time is indicated by the horizontal bar. Baseline values were 100  •  26 nM. 
The [Ca2+]i increases are on a nonlinear  scale. Gaps in the traces are due to additions  and stirring of the suspensions. All results are representative 
of three  experiments  and data  in vertical groups were collected at one time. 
1410  CD2 Signal Transduction  Requires  Functional  T  Cell Receptor or Fc"/RIIIA Table  1.  Increases  in [CaZ']~ Induced by Various Ligands and Crosslinkers in  TCR- Jurkat Cells 
Triggering agent 
Control cells  CD16  (GPI)  CD16  (T/M) 
F(ab')2  F(ab')  F(ab')2 
RAM;  RAM;  RAM;  F(ab')2 RAM; 
No crosslinker  1%  lgG  No crosslinker  1%  lgG  No crosslinker  1%  IgG  <0.0001%  IgG 
nM 
Anti-human CD3 
OKT3  F(ab')2  31  •  1  16  _+  2  30  •  5  29  +  8  35  •  4  23  •  3  12  +_  7 
Anti-human CD2 
(GT2  x  OKTll)F(ab"y)2  76  +  3  169  +_  17  76  •  5  172  •  14  91  _+  4  627  +_  30  203  •  30 
Anti-human CD16 
3G8  IgG  -  23  +_  5  -  46  +_  6  -  447  •  16  400  _+  25 
Cell populations  and ligands are as for Fig. 4. The final concentration of OKT3 F(ab')2 was 0.5 ~ag/ml, and that of (GT2  x  OKTll)F(ab'3~)2  was 
2.5 /~g/ml. Cells were pre-incubated  on ice for  1 h in 50/~1 of 50 ~g/ml 3G8.  The final concentration of the crosslinking mAb was 20/~g/ml. 
Values are differences in [Ca  2  § ]i before and after the addition  of the ligands,  and each represents the mean  •  SEM of three experiments.  Baseline 
values were  100  •  26 nM. In experiments  where  a gradual  rise in baseline was observed,  corrections  were  made for leakage of fura-2. 
order of magnitude with both preparations of F(ab')2 RAM 
crosslinker. 
T cell activation via human CD2 requires crosslinking of 
two CD2 epitopes. To achieve effective crosslinking, bispecific 
(GT2  x  OKTll)  F(ab'3')2  was  prepared.  This  bispecific 
anti-CD2 mAb generated signals of a similar magnitude in 
the control Jurkat cells and in theJurkat cells expressing CD16 
(GPI),  both  before  and  after  further  crosslinking  with 
F(ab')2 RAM containing 1% lgG. In Jurkat cells expressing 
the T/M form of CD16,  there was a similar rise in [Ca  2  +  ]i 
after the addition of the primary bispecific  anti-CD2 mAb. 
After additional crosslinking with F(ab'2) RAM containing 
1% IgG, however, there was a prompt large rise in [Ca  2  ~  ]i. 
After removal of the 1%  IgG from the F(ab')2 RAM,  the 
enhanced signal above that seen on untransfected cells or cells 
transfected with  CD16  (GPI) was no longer observed. 
The effect of the small amount of IgG on [Ca  2§ ]i levels 
was reflected not only in the magnitude of the Ca  2+ signals, 
but also in their kinetics. In the untransfected cells as well 
as in the cells expressing CD16 (GPI) and CD16 (T/M), the 
bispecific anti-CD2 mAb induced a sharp rise in [Ca  2§ ]i fol- 
lowed by a return to levels <50 nM above the baseline within 
3 min of adding the primary mAb. Within 3 min of adding 
m 
t_ 
aJ 
L~ 
.~  CD2 
j'I  0X-34) 
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the crosslinker, [Ca  2§ ]i levels were <40 nM above those at- 
tained before crosslinking in the untransfected cells and the 
cells expressing CD16 (GPI). In cells expressing CD16 (T/M), 
however, crosslinking of anti-CD2 mAb with F(ab')2 RAM 
containing 1% IgG induced a sustained increase in [Ca  2+ ]i. 
3  min after adding the crosslinker, the [Ca  2+ ]i levels were 
•200  nM above those observed immediately before the ad- 
dition of the crosslinker. Similar profiles were obtained using 
a  bispecific  (GT2  x  OKTll)  F(ab')3  comprising  two 
OKTll Fab' arms and one GT2 Fab' arm (data not shown). 
Ca 2+  Signals Generated via  CD2  in  the  Rat  NK  Cell 
Line.  The results in Jurkat cells suggested that the role of 
the CD2 antigen in signal transduction on NK cells should 
be re-examined. The previously described rat NK cell line 
RNK-16 (14) was studied for this purpose. The cells express 
high levels of CD2, are positive for the NK cell marker NKR- 
P1  (26),  and are negative for CD3  (Fig.  5). 
Representative profiles of Ca  2  + signals generated via CD2 
using the anti-CD2  mAb OX-34 in the form of IgG and 
F(ab')2 are shown in Fig.  6, and quantitative data are given 
in Table 2. When OX-34 IgG was used, the largest rise in 
[Ca  2+ ]i was obtained using IgG RAM as crosslinker.  The 
Ca  2  § signal was reduced when OX-34 IgG was crosslinked 
CD3 
(IF4) 
O"  iOI  li~  1~ 
Figure 5.  Flow cytometric  analysis 
of a rat  NK cell line RNK-16.  The 
CD2, NKR-Pl, and CD3 antigens were 
labeled with the OX-34, 3.2.3, and 1F4 
mAbs,  respectively. The dotted  lines 
show  labeling  with  isotype-matched 
negative  control  antibodies  F23.1 
(IgG2a) in the case of OX-34, OX-21 
(IgG1) in the case of 3.2.3, and W6/1 
(IgM)  in the case of 1F4. CROSSLINKER 
RAM I~ 
A25 "I 
OX-34F(ab')2  ~A2~--03 
..,-- 
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Figure 6.  [Cg+]t responses of a rat 
NK cell line RNK-16 and of TCR + 
Jurkat cells expressing rat CD2. The 
OX-34 mAb was used as whole IgG or 
as OX-34 F(ab')z containing  <0.001% 
IgG (2/~g/ml final concentration) and 
crosslinked with RAM, F(ab')2 RAM 
containing 1% lgG or F(ab')z RAM 
containing <0.0001%  IgG (20/zg/ml 
final  concentration),  mAbs  (~,) and 
crosslinkers ( ~ ) we~ added to the cells 
at the time points indicated. Values  fol- 
lowing  the  A  indicate  increases in 
[Ca2+]i in nanomolar above the base 
lines and the time is indicated by the 
horizontal bar. Baseline  values  were 136 
+  14 nM. The [Ca2+]i increases  are on 
a nonlinear  scale. Gaps in the traces are 
due to additions and stirring of the sus- 
pensions. 
with F(ab')2 RAM containing 1% IgG, and a similar sized 
signal  was  seen  when  pure  F(ab')2  RAM  crosslinker  was 
used.  Crosslinking  of  OX-34  F(ab')2,  which  contained 
<0.001%  of IgG (data not  shown) with IgG RAM,  gave 
a large signal that was diminished when the RAM was replaced 
by  F(ab')2  RAM  containing  1%  IgG  as  crosslinker.  No 
signal was transduced when the OX-34  F(ab')2 was cross- 
linked using pure F(ab')2 RAM.  A  similar  titration  effect 
was seen in a second rat NK cell line, A181, which was main- 
tained by passage in Fisher rats (L.L. Spruyt and M.J. Glennie, 
unpublished data).  In this line, the crosslinking of OX-34 
F(ab')2 (<0.001%  IgG)  with highly purified F(ab')2 RAM 
(<0.0001%  IgG) also failed to transduce a signal. The func- 
tional  effectiveness  of the  OX-34  F(ab')2  was  tested  on  a 
TCR + Jurkat cell line expressing rat CD2 (2). Crosslinking 
of rat CD2 on these cells, using the OX-34 F(ab')2 followed 
by pure F(ab')2 RAM, induced a rapid and sustained increase 
in [Ca 2 +]i (Fig.  6). 
Discussion 
There is a substantial amount of evidence that the TCR/ 
CD3 complex is required for eflident signaling via CD2 (1, 
2).  The key points are as follows: (a) downmodulation of 
CD3 prevents stimulation via CD2 (9);  (b) CD2 expressed 
on an insect gut epithdial line (7) or a routine L fibroblast 
line (8) does not function as a target for signal transduction; 
(c) cell lines that lack the TCR/CD3  complex or that are 
defective in their TCR/CD3 complex show reduced signaling 
via CD2. 
There is some ambiguity in the data with respect to the 
Jurkat T  call leukemic lines.  The TCR/CD3 + CD2 + line 
J.Caml, which has a defective signaling pathway through the 
TCR/CD3 complex, is not responsive to CD2 ligands. Cor- 
rection of the signaling defect restores the response (33), 
demonstrating the necessity for a functional TCR/CD3 com- 
plex. Other studies (33-35) also showed that CD2 does not 
function as  a  target  for activation in TCR/CD3-  Jurkat 
Table  2.  Increases in [Ca2+]i Induced in the Rat NK Cell Line RNK-16 
OX-34 IgG  OX-34  F(ab')2 
F(ab')zRAM;  F(ab')zRAM;  F(ab')2RAM;  F(ab')2RAM; 
RAM  1%  IgG  <0.0001%  IgG  RAM  1%  IgG  <0.0001%  IgG 
nM 
232  +  10  108  +  10  83  _  11  180  +  12  48  _+  10  10  _+  5 
Cell populations  and ligands are as for Fig. 6. The final concentration of OX-34 IgG and OX-34F(ab')2 was 2/~g/ml, and that of the crosslinking 
mAb 20/~g/ml. Values are differences in [Ca  2+ ]i before and after the addition of the ligands, and each represents the mean _+ SEM of three experi- 
ments. Baseline values were 136  +  14 nM. In experiments where a gradual rise in baseline was observed, corrections were made for leakage of fura-2. 
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not occur and transfection with ~/chain cDNA restored the 
potential to be activated via crosslinking of CD2 (33, 35). 
However,  in  other  studies,  activation  via  CD2  has  been 
reported to occur in TCR/CD3-  Jurkat cell lines,  and this 
was correlated with CD2 expression at high levels by Ohno 
et  al.  (34).  In  another  case  (36),  activation  via  CD2  on 
TCR/CD3- Jurkat cell lines has been attributed to the pres- 
ence of TCR/CD3 expression in amounts below the limits 
of detection by flow cytometry (35). Overall, the results argue 
that et~cient activation via CD2 requires the presence of the 
TCR/CD3  complex. 
The  present  experiments  were  done  with  the  TCR/ 
CD3-  Jurkat  cell  line J.RT3-T3.5,  which  is  mutant  for 
TCR ~/chain  expression and lacks detectable CD3 expres- 
sion at the cell surface.  In previous studies, rat CD2 trans- 
fected into these cells did not provide a target for activation 
in comparison with effective signal transduction via rat CD2 
on TCR/CD3 + Jurkat cells (2). In contrast to the rat CD2 
results, crosslinking of human CD2 on the TCR-  cells in 
the current work did give a Ca  2+  signal.  The crosslinking 
reagent  was  a  F(ab'3')2  heterodimer  reacting  with  two 
different epitopes of CD2 and this was further crosslinked 
with F(ab')2 RAM. However, a much larger signal was seen 
when the TCR-  cells were transfected with CD16 (T/M) 
and crosslinked with anti-CD16 antibody. Also on the CD16 
(T/M) § cells,  a large signal was seen with crosslinking via 
CD2,  but  only when  the crosslinking  F(ab')~  RAM con- 
tained some IgG. Without this the expression of CD16 (T/M) 
did not potentiate larger signals via the CD2 molecule and 
transfection with CD16 (GPI) did not potentiate signals under 
any circumstances. There are numerous studies showing that 
expression of CD16 (T/M) at the cell surface requires associ- 
ation with ~" or 3' chains but not other chains of the TCR/CD3 
complex (13).  Thus,  we conclude that  the expression of ~" 
chains in a complex lacking the rest of the TCR/CD3 mole- 
cules does not  potentiate  signaling  via CD2. 
The results in Jurkat cells lead us to re-examine signal trans- 
duction via CD2 on NK cells using the OX-34 mAb in the 
form of F(ab')2  that  contained <0.001%  IgG.  In this NK 
cell line and also in line A181, which has recently arisen in 
a Fisher rat (L.L. Spruyt and M.J. Glennie, unpublished data), 
there was no rise in [Ca  2  +  ]i after crosslinking of CD2 in the 
absence of involvement  of the Fc receptor CD16  (T/M). 
The present  studies in TCR-  Jurkat  cells  and NK cells 
are in accord with recent data in which a chimeric protein, 
made by linking the extracellular  and transmembrane domains 
of CD8 to the cytoplasmic domain of ~', was transfected into 
the  TCR/CD3-  J.RT3-T3.5 Jurkat  cell line  and  was ex- 
pressed at the cell surface as a homodimer. These Jurkat cells, 
expressing the chimeric CD8-  ~" mutants in the absence of 
a TCR/CD3 complex, were unresponsive to combinations 
of stimulating  anti-CD2  mAbs  as  measured  by  calcium 
fluorimetry (37). 
An Fe7 m:eptor ectodomain-independent triggering mech- 
anism has recently been proposed in which ~'/3' dimers may 
confer a TCK-independent signal transduction pathway upon 
CD2  in  TCR/CD3-  T  cells  or  NK  cells  (38).  In  this 
system, stimulation  of human CD2,  expressed on the sur- 
face of a murine mast cell line, leads to a rise in [Ca  2  § ]i, Ib6 
production, and histamine release. These results were obtained 
using the anti-CD2  mAbs both in the form of whole IgG 
and  as  F(ab')2  fragments  that  were  >95%  pure  on  SDS- 
PAGE. Given the pronounced effect of trace amounts (1%) 
of IgG in our F(ab')2  RAM preparation,  it is possible that 
effects demonstrated in the murine mast cell line were due 
to co-stimulation  of CD16  (T/M)  and CD2. 
Taken together,  the results in NK cells indicate that,  de- 
spite the expression of functional ~'/3' dimers, CD2 appears 
to require additional elements such as other CD3 chains to 
couple it to the cellular signal transduction pathways.  The 
primary function of CD2 may be to act as an adhesion mole- 
cule synergizing with the TCR/CD3 signal transduction com- 
plex in T  cells  when  antigen  is recognized in  the context 
of MHC  or  synergizing  with  the  Fc  receptor  complex 
Fc3,RIIIA when immune complexes are bound by NK cells. 
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